|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
In this review, the authors summarize the clinical results achieved with two specific strategies in hematological malignancies: chimeric antigen receptor (CAR) and T cell receptor (transgenic TCR) redirected T cells.
|
28978241 |
2018 |
|
TRBV20OR9-2
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Therefore, we have investigated if some cancer mutations found recurrently in hematological malignancies encode immunogenic neoantigens presented by common European Caucasoid HLA class I alleles and can form targets for TCR gene therapy.
|
30001747 |
2018 |
|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
The isolation of T-cell receptor (TCR) genes directed against neoantigens and their retransduction into peripheral T cells may provide a new form of ACT.Genetic modifications of T cells with chimeric antigen receptors (CARs) have demonstrated remarkable clinical results in hematologic malignancies, but are so far less effective in solid tumors.
|
28114254 |
2017 |
|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
In this study, we retrospectively analyzed six children with hematologic malignancies who received TCR-haploidentical second HSCT for primary GF.
|
28845543 |
2017 |
|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
T-cell receptor (TCR) gene transfer is an attractive strategy to equip T cells with defined antigen-specific TCRs using short-term in vitro procedures to target both hematological malignancies and solid tumors.
|
23364317 |
2013 |
|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
TCRs directed against the minor histocompatibility antigen (MiHA) HA-1 are good candidates for TCR gene transfer to treat hematologic malignancies because of the hematopoiesis-restricted expression and favorable frequency of HA-1.
|
21109688 |
2011 |
|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
In this review we discuss the current status of TCR gene transfer for the treatment of hematological malignancies.
|
18368589 |
2008 |
|
TRBV20OR9-2
|
0.090 |
GeneticVariation
|
group |
BEFREE |
A PCR technique was used in this study to investigate the pattern of clonal TCR delta gene rearrangement in Hong Kong Chinese patients with non-T-cell hematological malignancies.
|
8876635 |
1996 |
|
TRBV20OR9-2
|
0.090 |
Biomarker
|
group |
BEFREE |
Our findings suggest that the coexistence of JH and TcR gene rearrangements, frequently detected in acute leukemia, may also be observed in hematologic malignancies derived from more differentiated cells.
|
1847340 |
1991 |